Navigation Links
Tengion Appoints Diane Jorkasky, M.D., to its Board of Directors
Date:8/15/2011

ogy, internal medicine and clinical pharmacology.

"I am excited to join the Tengion Board of Directors at this critical juncture for the Company," said Dr. Jorkasky. "There is enormous potential in regenerative medicine and in Tengion's platform and I look forward to the opportunity to work with this seasoned group of scientists and entrepreneurs to help realize that promise."

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications.  An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.  The Company's lead preclinical candidate is the Neo-Kidney Augment, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.  Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment for the treatment of neurogenic bladder.  Tengion has worldwide rights to its product candidates.


'/>"/>
SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
4. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
5. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
8. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
9. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
10. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
11. Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... published in the Proceedings of the National ... showed when ibrutinib (IMBRUVICA ® ) was combined ... of tumor growth was enhanced suggesting a greater ... cancers and solid tumors with the combination. IMBRUVICA ...
(Date:2/27/2015)... 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... its pro forma net operating loss (NOL) guidance and ... financial position.  Isis, significantly improved financial results were due ... in payments the Company received from its partners.  Isis, ... a nearly 60% improvement over its 2013 NOL of ...
(Date:2/27/2015)...   Synageva BioPharma Corp. (Synageva) (NASDAQ: ... therapeutic products for rare diseases, joins the National ... for Rare Diseases™ (EURORDIS™), The Global Genes Project™, ... Disease Day. On the last day ... other participants conduct special events to raise awareness ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... Inc. (NYSE AMEX: ULU),announced today that an Australian ... the Therapeutic Goods Administration approving the marketing of Altrazeal® ... Australia, Kerry P. Gray, President and CEO of ULURU, ... commercialization of Altrazeal®.  Strategically this is an important market ...
... prostate cancer surgeon , Dr. David Samadi often takes ... join the prostate cancer fight overseas. As a ... and hands-on support is a vital part of the growth ... in countries such as the Netherlands, France, Dominican Republic and ...
Cached Medicine Technology:ULURU Inc. Announces Approval to Market Altrazeal® in Australia 2ULURU Inc. Announces Approval to Market Altrazeal® in Australia 3The Prostate Cancer Foundation Builds Momentum in China 2The Prostate Cancer Foundation Builds Momentum in China 3
(Date:2/28/2015)... February 28, 2015 Kaylie Corrigan, Outdoor ... treatment center , and current student obtaining her Masters ... implemented a weekly forum in psychoeducation on substance use ... Flagstaff, AZ as part of her studies. , “Even ... for support and counseling at the high school and ...
(Date:2/28/2015)... Viejo, California (PRWEB) February 28, 2015 Developers ... the release of a new overlay plugin for Final Cut ... Film Studios. , “FCPX Overlay Chromatic gives users total control ... said Christina Austin, CEO of Pixel Film Studios. “FCPX Overlay ... maintaining an easy to use interface.” , FCPX Overlay Chromatic ...
(Date:2/28/2015)... 28, 2015 The World Scout League ... materials to potential EMTs and firefighters, recently announced its ... a way to raise charitable donations for age-related research. ... Columbia, will be held on March 29, 2015; registration ... begin at 3:30 p.m. , To participate in ...
(Date:2/27/2015)... OnChip Devices , a world ... wire bondable, silicon ESD (Electrostatic Discharge) protection diodes targeted ... ESD88NP and ESD88PN are designed ... and IC products. These Zeners exhibit no device ... devices meet the requirements of IEC61000 and safely dissipate ...
(Date:2/27/2015)... February 27, 2015 On March ... and the National Cancer Institute (NCI) will co-host ... the National Institutes of Health (NIH), in Bethesda, ... is dedicated to medical professionals and scientists who ... to the general public, including patients, their families, ...
Breaking Medicine News(10 mins):Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3
... , ... new market research report is available in its catalogue: ... , http://www.reportlinker.com/p0166825/Antibiotic-Resistance-and-Antibiotic-Technologies-Global-Markets.html , Provide an in-depth ... antibiotics technologies , Offer an analysis of antibiotics resistance ...
... , WEDNESDAY, Dec. 2 (HealthDay News) -- In the ... patients in the United States have improved modestly, a ... more than 100,000 patients diagnosed with stage 4 non-small ... patient information was in the U.S. National Cancer Institute,s ...
... have metabolic syndrome, study finds , WEDNESDAY, Dec. 2 ... overweight college football players from being at higher risk ... disease, a new study suggests. , Researchers studied linemen ... obese. Of those, 42 percent had metabolic syndrome, a ...
... Va., Dec. 2 By now, most people have heard of ... the latest product on the market is now available at the ... at the amazingly low price of $14.99. , "This new product ... very low price, before making a bigger investment in a smokeless ...
... MONTREAL, Dec. 2 /PRNewswire/ - As part of its continued ... part of Pfizer, has pledged more than 40 million international ... Hemophilia (WFH). This is the largest donation ever made to ... impact to advance the WFH,s goals. , "This donation will ...
... , KNOXVILLE, Tenn., Dec. 2 TeamHealth ( www.teamhealth.com ... of Naples-based Emergency Physicians of Naples, LLC (EPN). Since ... Healthcare System to staff the emergency facilities at the Downtown ... EPN also provides the staffing for two stand-alone urgent care ...
Cached Medicine News:Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 2Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 3Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 4Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 5Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 6Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 7Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 8Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 9Health News:Gains Made in Lung Cancer Survival 2Health News:Oversized College Football Players May Face Heart Risks 2Health News:A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product 2Health News:The WFH receives the largest humanitarian aid donation in its history - Donation represents more than 40 million international units to the WFH 2Health News:TeamHealth Acquires Emergency Physicians of Naples, LLC 2
... the pain and hassle of testing. Unlike ... device is the only one with a ... testing, with less hassle and improved safety. ... and no side-to-side motion for less skin ...
... improved ergonomics for today's exacting laboratory ... finger rest and the large display ... Finnpipette Digitals also feature soft-touch tip ... pend.) and super blow-out for 0.2 ...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,408-9) or contact custom...
Medicine Products: